Table 1.
Clinical characteristics of CF nasal cell donors and expansion of CF nasal cells by EpiXTM technology.
| Genotype | Age (years) | Sex | Sweat NaCl (mM) | FEV-1% | Number of brushed cells | Days to 50 million cells | Passage number | Population doublings |
|---|---|---|---|---|---|---|---|---|
| F508del/R117H-7T | 6 | M | 45 | 71 | 1,216,000BC | 29 | 3 | 8.7 |
| F508del/F508del | 17 | M | 103 | 56 | 596,000 | 26 | 3 | 10.4 |
| F508del/c.850dupA | 20 | F | 108 | 109 | 20,000 | 31 | 4 | 11.6 |
| R334W/406-1G>A | 3 | F | 113 | N/A | 52,000 | 29 | 3 | 8.7 |
| CFTRdele2,3/CFTRdele2,3 | 4 | F | >100 | N/A | 100,000 | 29 | 3 | 10.4 |
Cells were expanded in EpiXTM media over a period of 26–31 days. Population doublings refers to the total number of times that cells in a population have doubled. Sweat test and lung function measurements (FEV1%) are listed from available patient data prior to cell collection. N/A, not available; BC, sample contained red blood cells.